.png)
Injectable Exosome in Australia: MCT-Based Protocol Combining Photothermal Biomodulation and Microneedling for Refractory Melasma
Introduction: Investigating Regenerative Approaches to Refractory Melasma
Melasma is a chronic pigmentation disorder that can be difficult to manage, particularly when conventional treatments provide limited improvement. While established therapies remain important, interest is growing in regenerative approaches involving microneedling, platelet-rich plasma (PRP) and exosome-related research.
For clinicians exploring injectable exosome approaches in Australia, a 2026 case report published in Clinical, Cosmetic and Investigational Dermatology investigated microneedling combined with MCT-processed autologous Exosomes in a 35-year-old patient with refractory melasma. Following three monthly sessions, researchers reported visible lightening in the affected facial areas, with no adverse effects observed.
MCT Meta Cell Technology: Exploring Photothermal Biomodulation
Meta Cell Technology (MCT) is a system used to precondition autologous blood-derived products through photothermal biomodulation. In the reported case, researchers selected the MCT System’s “Exosomes” preset to process PRP before intradermal administration.
The approach was intended to promote platelet-derived exosome release through controlled light exposure and temperature. It provides an example of how photothermal biomodulation is being investigated within regenerative dermatology.
Treatment Protocol: Combining MCT Processing With Microneedling
The published procedure involved four main stages.
Step | Procedure | Parameters |
1. Autologous PRP Preparation | Whole blood was collected and centrifuged to isolate the PRP fraction, which was then transferred into an MCT Kit. | 20 mL whole blood; 3.2% sodium citrate; 10 mL PRP |
2. Photothermal Biomodulation | PRP was processed using the MCT System’s “Exosomes” preset. | Blue light: 467 nm; energy: 1 J/cm²; temperature: 37°C; duration: 10 minutes |
3. Robotic Microneedling | Antisepsis was performed before robotic microneedling of the affected melasma areas. | No radiofrequency used |
4. Intradermal Administration | Preconditioned autologous Exosomes was injected intradermally at each mapped point. | Grid spacing: 1 × 1 cm; volume: 0.25 mL per point |
The sequence combined microneedling with intradermal administration of the processed autologous product. These parameters describe the published case protocol and should not be interpreted as an established treatment recommendation for melasma
Platelet Signalling and Skin Regeneration
Melasma is influenced by multiple biological factors, including ultraviolet exposure, oxidative stress, inflammatory signalling and interactions between melanocytes and surrounding skin cells.
Exosomes are extracellular vesicles involved in intercellular communication. Research has investigated their potential roles in inflammatory modulation and tissue repair. Platelets also contain growth factors and signalling molecules associated with regenerative processes.
Photothermal biomodulation is being explored as a way to precondition autologous Exosomes and influence platelet activity and exosome release. These mechanisms provide a rationale for further investigation, but their specific contribution to melasma improvement remains uncertain.
Clinical Results: Visible Improvement After Three Monthly Sessions
After three monthly sessions, the researchers reported visible lightening of the malar and temporal regions. Clinical photographs and stereophotogrammetric comparisons were used to assess changes, and alterations in vascularisation were also noted.
The procedure was reported to be well tolerated, with no complications or adverse effects observed in this patient.
When evaluating injectable exosome approaches in Australia, clinicians should also consider the exact nature of the product or procedure being discussed. An Autologous Injectable Exosomes preparation intended to promote exosome release is not interchangeable with a standalone exosome formulation.
Conclusion: An Early Clinical Insight Into MCT-Based Regenerative Research
The 2026 case report offers an early clinical insight into combining microneedling with MCT-processed autologous exosomes for refractory melasma. Visible improvement was reported after three monthly sessions, highlighting the potential relevance of photothermal biomodulation in regenerative dermatology.
For clinicians exploring injectable exosome approaches in Australia, these findings provide a basis for further investigation, not definitive evidence of efficacy. Larger controlled studies with standardised outcome measures and longer follow-up are needed to determine treatment effectiveness, safety and durability.
Reference
Leite Crivelin L, Tomasi-Batiston G. Microneedling Combined with Photothermal-Biomodulated Autologous PRP to Enhance Exosome Release in Refractory Melasma: A Case Report. Clinical, Cosmetic and Investigational Dermatology. 2026;19:596645. https://doi.org/10.2147/CCID.S596645
Explore MCT with Athena BioMed
Discover how MCT Meta Cell Technology uses photothermal biomodulation to support research into platelet-derived exosome release and regenerative applications.
Explore MCT with Athena BioMed to learn more about the technology, its clinical applications and its role in the evolving field of injectable exosome research in Australia.
